Skip to Main Content

Sometimes, regulators giveth with one hand, and taketh away with the other.

This is what Gilead Sciences (GILD) experienced this week, as the European Commission on Monday approved its CAR-T gene therapy for two aggressive forms of blood cancer. But on Tuesday, the U.K.’s cost-effectiveness watchdog declined to recommend government coverage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.